ASLI SISLI RAMON

Mission: Launching First Ophthalmology Product of Roche in Germany in a highly-competitive market

Been appointed as the new integrated (commercial, medical and access) strategy lead of the Ophthalmology team in the middle of a difficult launch:

• Achieved market leadership in biggest patient segment at the end of the year
• Discovered additional market adaption and expansion opportunities for the launch product, thus increased sales ambition more than double
• Solved cross-functional team issues by providing clarity on goals, aligning teams along the key tactics and restructuring, where needed.

Mission: Preparing Roche to enter Alzheimer's Market in Germany

Joined the team during the transition from Pipeline to Commercial Team:

• Developed integrated (Commercial, Medical, Access) Go-to-market strategy of the launch product
• Achieved clarity and alignment on cross-functional work packages to deploy the launch strategy
• Acted on System Shaping initiatives with Key Opinion Leaders to prepare German Healthcare System for innovative Alzheimer's Drugs
  
  

Mission: Growing with an in-market disease area despite severe cost containments

Being new to German market, gained local market knowledge in a very short time:

• Developed integrated disease area strategy for Genitourinary cancers (Bladder, Prostate, Renal) for the German affiliate
• Aligned commercial and medical teams along common goals & initiatives
• Prepared tactical launch plans for the upcoming indications
• Achieved to increase market share in mature indications in face of strong competition

• In the role as Pricing Manager for Perjeta in Breast Cancer, assisted in negotiation strategy development in line with commercial goals and supported the negotiation team along the negotiation process with the national payer (GKV-SV)
• In the role as Pipeline Strategy Lead for Crovalimab in Hemoglobinuria, ensured Commercial Development Plan and Global Integrated Strategy Plan reflect local market needs for successful launch

• Co-developed and rolled-out Product Pricing Policies for all portfolio and supported countries to reach target price at optimal access level
• Co-created Flexible Pricing Solutions together with countries to overcome country specific access hurdles
• Approved Roche prices (registered, contracted and tender) in her responsibility area of 50+ markets
  

• Defined Business Analytics Model for small, mid and large size countries. Improved numbers of FTEs in key emerging markets in less than 1 year
• Initiated & Led the 1st Regional Business Analytics Conference in EEMEA for closing knowledge/skill gaps in the region. Established Business Analytics Network among 20 markets.
• United forecasting approach for strategic products in top12 EEMEA markets

• Integrated patient cascade forecasting into regional business planning cycle for enhanced budget review dialogs
• Coached and collaborated with 31 diverse markets and produced reliable regional forecasts on strategic product sales, biosimilars impact, new product uptakes and market access solutions
• Represented CEMAI in Biosimilars Readiness Global Taskforce and developed Innovative Pricing Business Case Model with Global Pricing

• Defined and executed prelaunch & launch activities of Bonviva (Osteoporosis). Achieved #1 place in market share (21%) at the end of the first launch year
• Led Tamiflu (Influenza) during pandemic bird flu and prevented product supply shortage through early diagnosis & communication of the risk
• Pioneered field force e-detailing concept in Turkey

• Achieved highest key account sales in her territory for Seretide in Asthma